Resolutions from Swedish Orphan Biovitrum AB’s (Sobi™) Annual General Meeting (AGM)

The Sobi AGM convened earlier today in Stockholm and voted in favour of the
resolutions proposed at the meeting, including:

Adoption of the profit and loss statements and balance sheet and discharge of
liability

The AGM adopted the income statements and the balance sheets and approved the
proposal to carry forward the retained profits of SEK 4,882,438,248.

The board members and the chief executive officer were discharged from liability
for the financial year 2015.

Election of Board of Directors, remuneration to the Directors and election of
Auditor

The ordinary board members Annette Clancy, Matthew Gantz, Lennart Johansson,
Helena Saxon and Hans GCP Schikan were re-elected and Håkan Björklund, Theresa
Heggie and Jeffrey Jonas were elected as new board members. Håkan Björklund was
elected chairman of the Board.

Håkan Björklund has an extensive international background in the life science
industry, from both R&D and sales and marketing. He has experience of leading
healthcare companies in expansive development phases. Håkan Björklund owns
15,800 shares in the company and is independent in relation to the company and
its management and in relation to the company´s principal shareholders.

Theresa Heggie has several years’ of experience from a number of positions with
a global responsibility within, among other things, sales and marketing of
pharmaceuticals. Theresa Heggie does not have any shares in the company and is
independent in relation to the company and its management and in relation to the
company´s principal shareholders.

Jeffrey Jonas has more than 20 years’ of experience from research as well as
marketing within the pharmaceuticals and healthcare industries. Jeffrey Jonas
does not have any shares in the company and is independent in relation to the
company and its management and in relation to the company´s principal
shareholders.

The AGM approved the compensation to the Board in accordance with the nomination
committee’s proposal.

Ernst & Young was re-elected as auditor of Sobi until the end of the AGM 2017.

Principles for remuneration for the management, long-term incentive programme,
authorisation for the Board of Directors to resolve on the issuance of new
shares and/or convertible bonds and/or warrants, and transfer of own shares

The AGM approved the proposed guidelines for remuneration for the management.

The AGM also approved the Board’s proposal regarding the implementation of a
long-term incentive programme, and hedging arrangements in respect of the
programme including a directed issue of no more than 188,142 series C shares,
authorisation for the Board to decide on a repurchase of all issued series
C shares and transfers of no more than 1,276,826 own common shares to programme
participants.

The AGM also approved the Board’s proposal regarding the approval to authorise
the Board to resolve on the issuance of new shares and/or convertible bonds
and/or warrants. The number of shares that may be issued, the number of shares
that convertible bonds may be converted into and the number of shares that may
be subscribed for by the exercise of warrants, may not exceed 30,000,000 shares
in total.

The Board’s proposal regarding transfer of no more than 303,346 own common
shares on the stock exchange for the purpose of covering certain payments,
mainly social security contributions, that may occur in relation to the Share
Programme 2013, was also approved by the AGM.

For full details on each proposal adopted by the AGM please refer to
www.sobi.com.

---

About Sobi™
Sobi™ is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Haemophilia, Inflammation and Genetic diseases. We also market a
portfolio of speciality and rare disease products across Europe, the Middle
East, North Africa and Russia for partner companies. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion
(USD 385 M) and approximately 700 employees. The share (STO:SOBI) is listed on
NASDAQ Stockholm.

For more information please contact

Media   relations       Investor   relations
Oskar   Bosson, Head    Jörgen   Winroth, Vice
of Communications       President, Head of Investor
                        Relations
T:   +46 70 410 71 80   T:   +1 347-224-0819, +1 212
                        -579-0506, +46 8 697 2135
oskar.bosson@sobi.com   jorgen.winroth@sobi.com

The information was released for public distribution on 24 May 2016 at 19:00
CET.